VIDEO: Margaret Powers, PhD, Speaks About the Impact of Obesity on Chronic Conditions

In this video, Margaret Powers, PhD, talks about obesity's impact on the management of chronic illnesses. Dr. Powers also talks about the benefits of obese patients losing 5% to 7% of body weight and working out 150 minutes a week to lower their risk of developing diabetes and other chronic conditions.

Related Videos

Related Content

Advertisement

April 15th 2025

FQHCs Show Low Engagement in Hypertension, Diabetes Trials

Pearl Steinzor

A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.

July 11th 2024

Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

April 14th 2025

Housing Instability Linked to Worse Type 2 Diabetes Outcomes

Pearl Steinzor

New study finds adults with stable housing have slightly better blood sugar and blood pressure levels.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

April 11th 2025

Health Risks of Microplastics Highlighted at Recent Medical Conferences

Brooke McCormick

Experts at leading health care conferences last month called for further research into the health effects of microplastics and prompted immediate action to limit exposure.

April 10th 2025

Elinzanetant Shows Promise for Menopausal Symptom Relief

Rose McNulty

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, desvenlafaxine, and gabapentin in a new meta-analysis.

Related Content

Advertisement

April 15th 2025

FQHCs Show Low Engagement in Hypertension, Diabetes Trials

Pearl Steinzor

A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.

July 11th 2024

Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

April 14th 2025

Housing Instability Linked to Worse Type 2 Diabetes Outcomes

Pearl Steinzor

New study finds adults with stable housing have slightly better blood sugar and blood pressure levels.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

April 11th 2025

Health Risks of Microplastics Highlighted at Recent Medical Conferences

Brooke McCormick

Experts at leading health care conferences last month called for further research into the health effects of microplastics and prompted immediate action to limit exposure.

April 10th 2025

Elinzanetant Shows Promise for Menopausal Symptom Relief

Rose McNulty

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, desvenlafaxine, and gabapentin in a new meta-analysis.